Nme2Cas9‐mediated therapeutic editing in inhibiting angiogenesis after wet age‐related macular degeneration onset

Sihui Hu, Yuxi Chen, Dongchun Xie, Kan Xu, Yunzhao Fu, Wei Chi, Haiying Liu, Junjiu HuangClinical 2023 · DOI

TL;DR

Researchers have developed a novel gene-editing approach using Nme2Cas9 delivered via AAV to target key genes involved in wet age-related macular degeneration (AMD). This method successfully inhibited the growth of new blood vessels (angiogenesis) in a mouse model, showing promise as a potential therapeutic strategy for this leading cause of vision loss.

What Problem Does This Paper Address?

Wet age-related macular degeneration (AMD) is a major cause of irreversible vision loss in the elderly, characterized by the abnormal growth of blood vessels (choroidal neovascularization, CNV) in the retina. This process is driven by the hypoxia-inducible factor (HIF-1α)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway. While current treatments involve repeated injections of anti-VEGF drugs, these can have side effects and require ongoing administration. Gene editing offers a potential for more sustained and targeted therapeutic intervention. However, previous gene editing studies primarily focused on preventing CNV, and there was a lack of validation for therapeutic intervention after CNV has already begun, which is critical for clinical application. This paper addresses this gap by investigating the efficacy of gene editing to disrupt key genes in the VEGF pathway after the onset of wet AMD in a preclinical model.

Methods

The study employed a single adeno-associated virus (AAV) vector system to deliver Nme2Cas9, a smaller Cas9 ortholog, along with specific guide RNAs (sgRNAs). This system was designed to target three key genes in the VEGF signaling pathway: Hifla, Vegfa, and Vegfr2.

  • sgRNA Design and AAV Vector Construction: sgRNAs were computationally designed for high on-target specificity and cloned into an all-in-one AAV vector expressing Nme2Cas9.
  • In Vitro and In Vivo Editing Efficiency: Mouse embryonic stem cells (E14) and mouse retinal pigment epithelial (RPE) cells were used to assess editing efficiency using T7 endonuclease I (T7E1) assays and targeted deep sequencing.
  • Laser-Induced CNV Model: A standard mouse model of wet AMD was established by laser photocoagulation to induce CNV.
  • Therapeutic Intervention: AAV vectors carrying Nme2Cas9 and sgRNAs targeting Hifla, Vegfa, or Vegfr2 were delivered via subretinal injection at different time points after CNV induction.
  • Outcome Assessment:
    • CNV Lesion Area: Measured using isolectin-B4 staining and ImageJ analysis.
  • VEGF Protein Levels: Quantified using ELISA in RPE cells and retinal tissues.
  • Inflammatory and Oxidative Responses: Assessed via quantitative real-time PCR and immunofluorescence.
  • Retinal Function: Evaluated using full-field electroretinography (ERG).
  • Off-Target Effects: Predicted using Cas-OFFinder and analyzed by targeted deep sequencing.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Nme2Cas9 as an Efficient In Vivo Gene Editor: The study demonstrates that Nme2Cas9, delivered via a single AAV vector, can efficiently edit target genes in adult mouse retinas with high indel frequencies and a significant proportion of frameshift mutations, even within days of administration.
  • Vegfa as the Primary Therapeutic Target: While targeting Hifla, Vegfa, and Vegfr2 were explored, only the disruption of Vegfa showed a significant therapeutic effect in reducing CNV lesion size when administered early after CNV onset. This highlights the critical role of Vegfa in the later stages of CNV development and suggests it's a more direct target for intervention than upstream regulators like Hifla or downstream effectors like Vegfr2 in this context.
  • Timing is Crucial for Therapeutic Intervention: The study suggests that early intervention (Day 3 post-laser) with Vegfa targeting is more effective than later intervention (Day 6 post-laser), indicating that the window of opportunity for therapeutic benefit is critical.
  • Safety Profile of Nme2Cas9: The research found no significant off-target effects in the analyzed loci, and ERG results showed no retinal dysfunction, suggesting a favorable safety profile for Nme2Cas9-mediated gene editing in RPE cells for wet AMD therapy.
  • Downregulation of Inflammatory Markers: Nme2Cas9-Vegfa treatment not only reduced CNV but also downregulated inflammatory and oxidative responses, suggesting broader benefits beyond just inhibiting angiogenesis.

Key Results

  • Nme2Cas9 achieved efficient gene editing in vivo, with indel efficiencies up to 71.8% for Vegfa at 11 days post-injection.
  • Early intervention with Nme2Cas9 targeting Vegfa significantly reduced CNV lesion area by 49.5% compared to the control group.
  • Nme2Cas9 targeting Hifla or Vegfr2 did not show significant therapeutic effects on CNV lesion size.
  • VEGFA protein levels in RPE cells were reduced by 63.20% in the Nme2Cas9-Vegfa treated group.
  • No off-target effects were observed in the analyzed potential off-target sites for Vegfa, Hifla, and Vegfr2.
  • ERG measurements indicated no significant retinal dysfunction after Nme2Cas9-Vegfa treatment.

Limitations and Future Work

  • Limited Observation Period: The laser-induced CNV model has a relatively short observation period (around 10 days), which may not fully capture the long-term effects of targeting Vegfr2.
  • AAV Serotype Specificity: The study used AAV8, which has limited specificity for vascular endothelial cells. Future work could explore other AAV serotypes for improved targeting.
  • Long-Term Efficacy and Safety: While short-term efficacy and safety were demonstrated, further investigation into the long-term therapeutic effects and potential side effects of Nme2Cas9-mediated gene editing is warranted, potentially using non-human primate models or clinical trials.
  • Target Selection and Timing: The study highlights the importance of selecting the right target gene and the optimal timing for intervention. Further research is needed to refine these aspects for clinical application.
  • Delivery Methods: While subretinal injection was used, alternative delivery methods like intravitreal injection might be preferable for certain applications, and the development of targeted delivery systems (e.g., LNPs) for RPE cells could further enhance safety and efficacy.

Summary updated

Abstract

This study provides proof-of-concept possibility of employing Nme<sub>2</sub> Cas9 for potential anti-angiogenesis therapy in wet AMD.
BibTeX
@inproceedings{hu2023nme,
  author = {Sihui Hu and Yuxi Chen and Dongchun Xie and Kan Xu and Yunzhao Fu and Wei Chi and Haiying Liu and Junjiu Huang},
  title = {{Nme<sub>2</sub>Cas9‐mediated therapeutic editing in inhibiting angiogenesis after wet age‐related macular degeneration onset}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1002/ctm2.1383},
}
Figure